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Edited by Jesus AvilaAbstract Microtubule associated protein tau, which is ex-
pressed in six alternatively spliced molecular isoforms in human
brain, is abnormally hyperphosphorylated in Alzheimer disease
and related tauopathies. Here, we show (i) that GSK-3a and
neither GSK-3b nor cdk5 can phosphorylate tau at Ser262 and
phosphorylation at Ser235 by cdk5 primes phosphorylation at
Thr231 by GSK-3a/b; (ii) that tau isoforms with two N-terminal
inserts (s4L, s3L) are phosphorylated by cdk5 plus GSK-3 at
Thr231 markedly more than isoforms lacking these inserts (s4,
s3); and (iii) that Thr231 is phosphorylated 50% more in free
tau than in microtubule-bound tau, and the phosphorylation at
this site results in the dissociation of tau from microtubules.
These ﬁndings suggest that the phosphorylation of tau at
Thr231 and Ser262 by cdk5 plus GSK-3, which inhibits its nor-
mal biological activity, is regulated both by its amino terminal
inserts and its physical state.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Alzheimerdisease (AD)and related tauopathies are character-
ized by neuroﬁbrillary degeneration of abnormally hyperphos-
phorylated tau [1]. The AD abnormally hyperphosphorylated
tau does not bind to tubulin but inhibits in vitro microtubule
assembly and disrupts preformedmicrotubules (MT) by seques-
tering normal tau, and high molecular weight microtubule asso-
ciated proteins (MAPs), MAP1 and MAP2 [2–4]. These
inhibitory eﬀects of the AD hyperphosphorylated are, however,
abolished by in vitro dephosphorylation by protein phospha-
tases (PP), especially PP-2A [5,6]. Despite its importance, the
molecular mechanism of the abnormal hyperphosphorylation
of tau is not fully understood.Abbreviations: AD, Alzheimer disease; PHF, paired helical ﬁlaments;
cdk5, cyclin-dependent protein kinase 5; GSK-3, glycogen synthase
kinase-3; PDPK, proline-dependent protein kinase; MT, microtubule;
PMSF, phenyl methyl sulfonyl ﬂuoride
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doi:10.1016/j.febslet.2006.09.060To date, over 25 abnormal sites have been identiﬁed at
which tau in paired helical ﬁlaments (PHF) is phosphorylated
[7]. The phosphorylation of tau at only some of these sites
might play a signiﬁcant physiological role. Tau can be phos-
phorylated at one or more of these abnormal sites by several
protein kinases (see [8]). Among these protein kinases, glyco-
gen synthase kinase-3 (GSK-3) and cyclin-dependent protein
kinase 5 (cdk5) are believed to be major enzymes involved in
Alzheimer abnormal hyperphosphorylation of tau. Cdk5 and
GSK-3 co-localize with Alzheimer neuroﬁbrillary degeneration
[9–12] and both kinases have been shown to produce neuroﬁ-
brillary degeneration of hyperphosphorylated tau in transgenic
mice [13,14].
Phosphorylation of tau at some of the sites inhibits its bind-
ing to MT and its ability to promote microtubule assembly
[2,15]. Thr231 and Ser262 are the two major sites phosphoryla-
tion of which by cdk5 followed by GSK-3 inhibits binding to
MT [16–18]. An important factor that might inﬂuence the phos-
phorylation of tau at speciﬁc sites that have received little atten-
tion to date is that tau is present in the brain in diﬀerent
substrate forms. In adult human brain, six isoforms of human
tau are present. These isoforms, which are generated from a sin-
gle gene through alternate mRNA splicing [19], vary in length
between 352 and 441 amino acids and diﬀer in whether they
contain three (s3, s3S, s3L) or four (s4, s4S, s4L) microtubule
binding domains of 31 or 32 amino acids each and none (s3, s4),
one (s3S, s4S) or two (s3L, s4L) N-terminal inserts of 29 amino
acids each. Furthermore, tau in brain is present in at least two
major pools: (i) as free tau; and (ii) as tau bound to MT.
In the present study, we compared (i) the phosphorylation of
tau isoforms with or without the N-terminal inserts by cdk5
and GSK-3, singly or in combination and their binding to
MT, and (ii) the phosphorylation of free and microtubule-
bound taus by these two protein kinases. We found (i) that
GSK-3a but neither GSK-3b nor cdk5 could phosphorylate
tau at Ser262; (ii) that both cdk5 and GSK-3a could phosphor-
ylate Ser-235; (iii) that phosphorylation of tau by cdk5 mark-
edly enhanced the phosphorylation of tau at Ser235 and
resulted in a robust phosphorylation of tau at Thr231 by
GSK-3, especially the GSK-3b; and (iv) that after phosphory-
lation by cdk5 and GSK-3, human tau isoforms bound to MT
diﬀerentially. The phosphorylation at Thr231 and Ser262 by
the above kinases and the consequent inhibition of binding
to MT were more in tau isoforms with the two amino terminal
inserts than the isoforms lacking the inserts. The phosphoryla-
tion of Thr231 and Ser262 was decreased in MT-bound taublished by Elsevier B.V. All rights reserved.
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Ser396, Ser404 and Ser422 was unchanged. These ﬁndings sug-
gest that the phosphorylation of tau at sites which aﬀect its
biological activity is regulated signiﬁcantly at the substrate
level.2. Materials and methods
2.1. Materials
Tau monoclonal antibodies (mAb) employed were as follows: M4 to
tau phosphorylated at Thr231 and Ser235 [20] was a gift from Dr. Y.
Ihara (University of Tokyo, Japan), 12E8 to tau phosphorylated at
Ser262 and/or Ser356 [21] was a gift from Dr. Dale Schenk of Elan
Pharmaceuticals (San Francisco, CA), and PHF-1 to tau phosphory-
lated at Ser396 and/or Ser404 [22] was a gift from Dr. P. Davies, Albert
Einstein College of Medicine (Bronx, NY). Polyclonal tau antibodies
92e to total tau and 102c to tau dephosphorylated at Ser46 were raised
in rabbits, as previously reported [23,24]. Polyclonal rabbit R145 to tau
phosphorylated at Ser422 was described previously [25]. Rabbit anti-
bodies pT231, pS236, and pS262 to tau phosphorylated at Thr231,
Ser235 and Ser262, respectively, were obtained from Biosource Intl.
(Camarillo, CA). Rabbit antibodies 127d to GSK-3b and 133d to
GSK-3a and GSK-3b were raised in our lab [10]. Polyclonal antibody
to GSK-3a was from Upstate Biotechnology, Inc. (Lake Placid, NY),
and monoclonal antibody to GSK-3b was from Transduction Labs
(San Diego, CA). Recombinant GSK-3b was purchased from Calbio-
chem (San Diego, CA). 125I-labeled anti-mouse and anti-rabbit IgG
antibodies were purchased from Amersham (Arlington Heights, IL).
[c-32P] ATP was purchased from ICN Biomedicals (Costa Mesa, CA).2.2. Methods
The human tau clones 23, 24, 39 and 40 (kindly provided by Dr. M.
Goedert) that encode for the isoforms s3, s4, s3L and s4L, respec-
tively, [19] were subcloned in E. coli and puriﬁed from cell extracts
as described previously [26]. pGEX-2T plasmids containing cdk5 and
p25, kind gifts from Dr. Jerry H. Wang (The Hong Kong University
of Science and Technology, Clear Water Bay, Kowloon, Hong Kong)
were expressed and puriﬁed from E.coli as GST fusion proteins [27].
The puriﬁcation of GSK-3 and cdk5 was as described [28]. The
GSK-3 preparation contained both a and b isoforms in 3:2 ratio
[26]. Cdk5 and GSK-3 were also puriﬁed by immunoprecipitation with
appropriate antibodies from rat brain extract. The 16000 · g brain ex-
tract, 50 lg protein was incubated with 2 lg of speciﬁc antibodies in
50 mM Tris, pH 7.4, 150 mM NaCl, 10 mM NaF, 1 mM Va3VO4,
2 mM EGTA, 1 mM phenylmethyl sulfonyl ﬂuoride (PMSF) and
5 lg/ml each of leupeptin, pepstatin and aprotinin. After incubation
overnight at 4 C, 30 ll of protein G immobilized on agarose beads
(Pierce, Rockford, IL) was added and the reaction mixture was further
incubated for 3 h with constant mixing. The incubated mixture was
then centrifuged and the beads were washed three times with immuno-
precipitation buﬀer, resuspended in 10 ll of the phosphorylation reac-
tion buﬀer, and used as a kinase.
MAPs-free tubulin was isolated from rat brain extract through two
temperature-dependent cycles of microtubule polymerization–depoly-
merization, followed by chromatography on cellulose [2]. Taxol-stabi-
lized MT were prepared by incubating MAPs-free tubulin (4 mg/ml)
with taxol (20 lM) in the presence of MES (0.1 M, pH 6.8), EGTA
(1 mM) and PMSF (1 mM) for 30 min at 37 C. The MT were col-
lected by centrifugation over a cushion of 0.125 M sucrose at
50000 · g for 30 min at 32 C.
Tau isoforms were phosphorylated at 30 C in a reaction mixture
normally containing 4.0 lM tau, 6 mM MgCl2, 10 mM 2-mercap-
toethanol, 0.25 mM [c-32P] ATP, and 40 mm HEPES (pH 7.5). Reac-
tions were initiated at 30 C by the addition of kinases. For
determination of 32P incorporation into protein, aliquots of the reac-
tion mixtures were removed at diﬀerent times, spotted on strips of
Whatman ﬁlter paper (31ET) and free [c-32P] ATP separated from
32P-labeled protein by ascending chromatography [26]. The 32P-labeled
tau on the ﬁlters was quantitated by Cerenkov counting in a scintilla-
tion counter. When prephosphorylation of tau was required, [c-32P]
ATP was replaced with unlabeled ATP. After incubation for 2 h at30 C, the reaction was stopped by heating at 95 C for 5 min and
denatured kinases removed by centrifugation (10000 · g for 10 min).
The extent of tau phosphorylation was determined in parallel experi-
ments using [c-32P] ATP. The heat-stable phosphorylated tau was then
used as a substrate for the second kinase. In controls, the incubation
was carried out without the ﬁrst kinase but otherwise treated identi-
cally as the samples for combination phosphorylation.
To analyze the binding of tau to MT, 0.47 lM tau (non-phosphor-
ylated or phosphorylated) was incubated with 7.4 lM taxol-stabilized
MT for 30 min at 37 C in buﬀer A (0.1 M HEPES, pH 6.8, 2 mM
MgCl2, 1 mM EDTA, 1 mM PMSF, 20 lM taxol and 1 mM GTP).
Tau bound to MT was separated from unbound tau by centrifugation
at 50000 · g for 30 min at 32 C on a cushion of 10% glycerol. The pel-
let was washed twice with buﬀer A and dried in a Speed Vac. The com-
bined supernatants were precipitated by acetone, centrifuged and the
precipitate was again dried by a vacuum concentrator. All samples
were electrophoresed in 10% SDS-polyacrylamide gels, transferred to
nitrocellulose and immunoblots probed with the rabbit polyclonal
phosphorylation-independent tau antibody, 92e (1/5000). The immu-
noreactive bands were quantitated. In each set, the supernatant (free
tau) and the pellet (bound tau) were calculated as percent of total
tau. To assay the release of MT-bound tau, the phosphorylation reac-
tion was stopped by cooling to 4 C and immediately centrifuged
(50000 · g) to separate tau which remained bound to microtubules
(pellets) from free released tau (supernatant).
Immunoblotting of tau by the diﬀerent antibodies was carried out as
described previously [1]. The following dilutions of the primary anti-
bodies were used: MT (1/1000), 12E8 (1/500), PHF-1 (1/500), 92e (1/
5000), 102c (1/1000) and anti-P-Ser422 (1/3000). Blots were then fur-
ther probed with anti-mouse or anti-rabbit IgG secondary antibodies
which were labeled with 125I. The immunoreactive bands were visual-
ized and quantitated by Fuji 1500 Phosphorimager Imaging System.3. Results
3.1. Phosphorylation of free and MT-bound tau by a
combination of cdk5 and GSK-3
To examine the regulation of the phosphorylation of tau by
its state of conformation as a substrate, we investigated the
phosphorylation of free and MT-bound taus by cdk5 and
GSK-3. For this purpose, we chose two tau isoforms (see
Fig. 1), s3 and s3L as free proteins and as bound to MT stabi-
lized with taxol. Prephosphorylation of MT-bound tau by
cdk5 increased the rate of subsequent phosphorylation by
GSK-3 by 25% in the case of s3L but not s3 (Fig. 2). On
the other hand, prephosphorylation of free s3 and s3L by
cdk5 increased subsequent phosphorylation by GSK-3 by
30% and 50%, respectively (Fig. 2C). These results suggest
that prephosphorylation by cdk5 stimulates the subsequent
phosphorylation by GSK-3 (i) more in tau with the N-terminal
inserts than the same protein without the inserts, and (ii) more
in free tau than the same as MT-bound protein.3.2. Binding of diﬀerent phosphorylated species of tau isoforms
to microtubules
Since the phosphorylation of tau at only some and not all
sites might be of physiological signiﬁcance, we investigated
whether the upregulation of the phosphorylation of tau due
to N-terminal inserts inhibited its binding to MT. We exam-
ined the eﬀect of phosphorylation by cdk5, GSK-3 or by com-
bination of cdk5 and GSK-3 on the binding of tau to MT
using s3, s4, s3L, and s4L. For all the four tau isoforms, the
kinase combination cdk5 followed by GSK-3 was most eﬀec-
tive for causing inhibition of tau binding to MT (Fig. 3A).
In contrast, no signiﬁcant increase in inhibition was observed
Fig. 1. Schematic representation of the structure of the four human
tau isoforms employed in the present study. Two of the isoforms (s3,
s3L) contain three repeat microtubule-binding domains, whereas the
other two isoforms (s4, s4L) contain four repeats (hatched areas 1, 2,
3, and 4). In addition, s3L and s4L contain two N-terminal inserts,
each 29 amino acids long (A and B). s3 and s4 lack such N-terminal
inserts. Bar diagram of s4L shows locations of eight Ser/Thr sites
phosphorylated by cdk5 plus GSK-3. N, N-terminal domain, P,
proline-rich region, and C, C-terminal tail. s4L, s3L, s4 and s3 are 441,
410, 383, and 352 amino acid long, respectively.
Fig. 2. Phosphorylation of free and microtubule-bound tau isoforms
(s3 and s3L) by a combination of cdk5 (K5) and GSK-3 (K3). s3 (A)
and s3L (B) as free (open symbols) or microtubule-bound (closed
symbols) incubated in the absence (s, d, n and m) or presence (h, j)
of cdk5 as described in Section 2. After 120 min at 30 C, the
phosphorylated taus (with non-radioactive ATP) were further phos-
phorylated by [c-32P] ATP and cdk5 (s, d) or GSK-3 (n, m, h and
j) for another 120 min at 30 C. Aliquots of the phosphorylation
mixture were removed at diﬀerent times, the reaction was stopped by
heating at 95 C for 5 min and denatured tubulin removed by
centrifugation (10000 · g, 10 min). The heat-stable phosphorylated
tau in the supernatant was spotted on ﬁlter paper and 32P incorpo-
ration was analyzed as described in Section 2; (h, j,) incubated with
cdk5, followed by GSK-3; (n, m) incubated without kinase, followed
by GSK-3; (s,d) incubated without kinase followed by cdk5. (C) 32P-
incorporation by second kinase in 120 min at 30 C. Open bars, free
taus; closed bars, MT-bound taus.
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phosphorylated by cdk5 (compare column K3K5 with column
K3 in each panel). For both s3L and s4L, phosphorylation by
cdk5 followed by GSK-3 combination resulted in 80% inhi-
bition of binding of phosphorylated tau to MT, whereas for
both s3 and s4, this inhibition was 40% (Table 1). Thus,
the presence of N-terminal inserts markedly reduced the bind-
ing of tau to MT when it was phosphorylated by a combina-
tion of cdk5 and GSK-3. Unlike the amino-terminal inserts,
the presence of the fourth microtubule binding repeat did
not signiﬁcantly aﬀect on phosphorylation by cdk5 and
GSK-3 the binding of tau to MT.
Next, we examined whether the N-terminal inserts or the
fourth repeat regulate the phosphorylation of the MT-bound
tau that aﬀects tau’s association to MT. For this purpose, we
ﬁrst bound tau to taxol-stabilized microtubules (tubulin/tau
molar ratio 15:1, well below the saturation level) and then dif-
ferent MT-bound tau species were phosphorylated by cdk5
and GSK-3, acting singly or in combination. The released
tau remained in the supernatant, whereas the MT-bound tau
was recovered in the pellet. The MT-bound tau identically
treated but without kinase(s) served as a control. We found
that 8% tau was released when MT-bound s3, s4, s3L and
s4L were incubated in phosphorylation buﬀer in the absence
of any kinase. When the MT-bound tau isoforms were phos-
phorylated by the combination of cdk5 and GSK-3, as a result
of this phosphorylation 24%, 25%, 49% and 46% of s3, s4, s3L
and s4L, respectively, were released, compared to the MT-
bound taus which were not phosphorylated (100%; Fig. 3B).
A comparison of these results to those in Fig. 3A revealed that
when phosphorylated by cdk5 plus GSK-3, MT-bound taus
behave diﬀerently from the free tau in associating to MT; the
MT-bound was 30% (s3, s4) to 300% (s3L, s4L) more asso-
ciated to MT than the corresponding free taus when phosphor-
ylated with cdk5 followed by GSK-3 (see Table 1). The fourth
repeat had no signiﬁcant eﬀect on the release of tau from MT
produced by phosphorylation by cdk5 and GSK-3 (compare
s3 with s4 and s3L with s4L in Table 1).3.3. Phosphorylation of tau at Thr231, Ser235 and Ser262 by
cdk5, GSK-3a and GSK-3b
While both Thr231 and Ser235 are canonical sites for pro-
line-dependent protein kinases (PDPK) and, thus, are expected
to be phosphorylated by the proline-dependent protein kinases
cdk5 and GSK-3, the phosphorylation of tau at Ser262, a non-
proline-dependent site, by these kinases has been controversial
[29–35]. Thus, before ascribing the eﬀect of the phosphoryla-
tion of tau to Thr231, Ser235 or Ser262 by cdk5 and GSK-3,
we investigated which of these three sites could be phosphory-
lated by the two kinases. For these studies, we employed
recombinant enzymes and as well each kinase puriﬁed by
immunoprecipitation with diﬀerent speciﬁc antibodies. We
found that GSK-3a and neither GSK-3b nor cdk5 could
phosphorylate tau at Ser262 (Fig. 4A and B). Both PKA and
Fig. 3. (A) Comparison of the binding of diﬀerent phosphorylated species of tau isoforms to microtubules, and (B) release of microtubule-bound tau
isoforms after phosphorylation by cdk5 and GSK-3. s3 (A), s4 (B), s3L (C) or s4L (D) was phosphorylated by cdk5 and or GSK-3, and its binding to
taxol-stabilized MT was determined (A). Alternatively, taxol-stabilized MT were phosphorylated as above and the release of tau from MT was
determined (B). Tau levels were assayed by immunoblots developed with phosphorylation-independent tau antibody 92e, and probed with 125I-
labeled secondary antibody. Immunoreactive bands were quantitated. All values are expressed as a percentage of the binding observed with non-
phosphorylated-s (100%). Data (means ± S.D.) are from four separate experiments.
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controls, as expected, phosphorylated s4L at Ser262.
cdk5 phosphorylated tau at Ser235 more robustly than
GSK-3a; the phosphorylation of tau at Ser235 by GSK-3b
was not detected (Fig. 4C). However, phosphorylation of tau
by cdk5 not only markedly enhanced the phosphorylation at
Ser235 but also resulted in a robust phosphorylation of
Thr231 by GSK-3, especially the GSK-3b.
3.4. Phosphorylation of free and MT-bound taus at diﬀerent
Alzheimer abnormal phosphorylation sites
To determine the speciﬁcity of the diﬀerences in the phos-
phorylation of tau at Thr-231/Ser235 and Ser262/Ser356 be-
tween the free and the MT-bound taus, we studied the
phosphorylation of these taus at several other abnormal sites.
With the aid of site-speciﬁc phosphorylation-dependent anti-
bodies, we examined the phosphorylation of eight sites
(Ser46, Thr231, Ser235, Ser262, Ser356, Ser396, Ser404 and
Ser422 in s3L and s4L, and all the above sites except Ser46
in s3 and s4, because s3 and s4 lack Ser46, which is in the
N-terminal inserts) which are known to be phosphorylated in
PHF-tau [7,36]. The antibody 102c binds to dephosphorylatedSer46, M4 binds to P-Thr231 and P-Ser235, 12E8 binds to
P-Ser262 and P-Ser356, PHF-1 binds to P-Ser396 and
P-Ser404, and anti-P-Ser422 antibody binds to P-Ser422.
Quantitative data from immunoblots revealed that the extent
of phosphorylation of Ser46 in both free and MT-bound taus
(s3L and s4L) were similar, which indicates that this N-termi-
nal site in both free and MT-bound taus is equally susceptible
to phosphorylation (Fig. 5). Thr231/Ser235 and Ser262/Ser356
were phosphorylated in free tau to the extent of 1.5-fold
higher in all the four isoforms studied compared to the corre-
sponding MT-bound taus, indicating that the proline-rich and
the repeat regions might be either involved in the binding of
tau to MT or present as less favorable conformation for phos-
phorylation in MT-bound tau. Both free and MT-bound taus
with two N-terminal inserts (s3L and s4L) were phosphory-
lated at Thr231/Ser235 and Ser262/Ser356 by cdk5 and
GSK-3 markedly more than taus lacking these inserts (s3
and s4). However, no such diﬀerences in the extent of phos-
phorylation of Ser396/Ser404 and Ser422 in free or MT-bound
taus were found. These ﬁndings suggested that C-terminal sites
were equally accessible for phosphorylation in both free and
MT-bound taus.
Table 1
Eﬀect of phosphorylation by cdk5, GSK-3 or cdk5 plus GSK-3 on the
binding of diﬀerent free or MT-bound tau isoforms to microtubules
s isoform
used
Kinase used
(1st and 2nd)
s bound to MT (%)
(phosphorylation
of sfollowed by
binding to MT)
s remained bound
to MT (%)
(phosphorylation
of MT-bound s)
s3 – 100 ± 2 100 ± 2
–, cdk5 98 ± 4 92 ± 3
–, GSK-3 89 ± 2 86 ± 2
cdk5, GSK-3 60 ± 4* 76 ± 1*
s4 – 100 ± 2 100 ± 3
–, cdk5 96 ± 2 92 ± 3
–, GSK-3 87 ± 2 86 ± 2
cdk5, GSK-3 56 ± 4* 75 ± 3*
s3L – 100 ± 2 100 ± 3
–, cdk5 93 ± 3 88 ± 2
–, GSK-3 89 ± 2 81 ± 2
cdk5, GSK-3 21 ± 3** 51 ± 5**
s4L – 100 ± 3 100 ± 2
–, cdk5 95 ± 2 88 ± 2
–, GSK-3 89 ± 2 81 ± 3
cdk5, GSK-3 19 ± 4** 54 ± 4**
*P < 0.05.
**P < 0.01.
Fig. 4. In vitro phosphorylation of recombinant human brain s4L at
Ser262 (A,B), Thr231or Ser235 (C), by diﬀerent protein kinases. s4Lwas
phosphorylated for 2 h at 30 C, followed by Western blots of the
samples developed with a rabbit antibody pS262 (Biosource Intl.) to tau
phosphorylated at Ser262 (A,B); mAb M4, a mouse monoclonal
antibody to tau phosphorylated at Thr231/Ser235 (C); a.pT231, a rabbit
antibody to tau phosphorylated at Thr231 (Biosource Intl.); and
a.pSer235, a rabbit antibody to tau phosphorylated at Ser235 (Biosource
Intl.). Cont, s4L treated identically but without any kinase; rc,
recombinant; IP, immunoprecipitated; UBI, antibody from Upstate
Biotechnology, Inc.; TL, antibody from Transduction Labs; 127d, a
rabbit antibody to GSK-3b [10]; cdk5 rc, recombinant cdk5 plus p25.
cdk5IP in (B) and a.pT231 staining of Cont in (C) are non-speciﬁc.
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three mutants of s4L, namely s4L (Ala231), s4L (Ala235) and
s4L (Ala262) in which Thr231, Ser235 and Ser262 were mutated
toAla231, Ala235 andAla262, respectively. As in Fig. 4, we ﬁrst
bound each mutant tau to taxol-stabilized microtubules and
then the diﬀerent MT-bound tau species were phosphorylated
by cdk5, GSK-3 or cdk5 followed by GSK-3. As a result of
phosphorylation, a part of the bound tau was released in the
supernatant, whereas the rest of it (still bound to MT) was
recovered in the pellet. The percent of mutant and wild-type
taus that remained bound to MT were compared (Fig. 6). After
phosphorylation by cdk5 plus GSK-3, the MT-bound Ala231
mutant tau remained bound to a25% higher extent compared
to MT-bound wild tau. Similarly, when phosphorylated by a
combination of cdk5 plus GSK-3, the MT-bound tau mutants
Ala262 and Ala235 were bound toMT to13% and2% high-
er extents, respectively, compared to MT-bound wild-type tau.
Thus, the phosphorylation of Thr231 and Ser262 in MT-bound
tau contributed 25% and 13% inhibition in binding to MT.
Previously, we have shown that, in free tau, phosphorylation of
Thr231 and Ser262 contribute almost equally (30%) towards
inhibition of binding of tau to MT [16]. Together, these results
suggest that, as a whole, the phosphorylation of Thr231 con-
tributes more than the phosphorylation of Ser262 in the inhibi-
tion of tau binding to microtubules.4. Discussion
Abnormal hyperphosphorylation of tau is a key biochemical
abnormality that leads to neuronal degeneration, the forma-
tion of neuroﬁbrillary tangles and the dementia syndrome
(for review see [8]). Thus, it is critical to understand the regu-
lation of the phosphorylation of tau. The hyperphosphoryla-
tion of tau appears to be controlled at both enzyme andsubstrate levels. The tau hyperphosphorylation at enzyme level
could occur by activation of one or more tau kinases and
decline in the activities of one or more tau phosphatases.
Furthermore, the activities of both kinases and phosphatases
can be modulated at substrate (tau) level. This could occur
due to diﬀerence in the prior phosphorylation states of tau
and as well as controlled by tau’s structure. Previous studies
had focused primarily on the levels of the activities of tau ki-
nases and tau phosphatases in AD brain and on the eﬀect of
phosphorylation of tau by one kinase on the subsequent phos-
phorylation by a second kinase (see Ref. [8]).
Fig. 5. Phosphorylation of Ser46, Thr231/Ser235, Ser262/Ser356, Ser396/Ser404 and Ser422 in free and microtubule-bound tau isoforms by cdk5,
GSK-3 and cdk5 plus GSK-3. s3, s4, s3L, or s4L (4 lM) were incubated in the phosphorylation reaction mixture as free (open bars) or microtubule-
bound (closed bars) in the absence () or presence of cdk5 (K5). After 2 h at 30 C, the phosphorylated taus were further phosphorylated by cdk5
(K5) or GSK-3 (K3) for 2 h at 30 C. The reactions were terminated by heating with SDS–PAGE sample buﬀer at 95 C for 5 min. The diﬀerent
phosphorylated tau species were immunoblotted with 102c (A), M4 (B), 12E8 (C), PHF-1 (D) and anti-PSer422 (E) antibodies, and probed with 125I-
labeled secondary antibodies. Data (means ± S.D.) are from four separate experiments.
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tau can also be regulated at the substrate level by tau’s struc-
ture. We found that tau isoforms with the two amino terminal
inserts (s4L, s3L) were more favorable substrates than tau iso-
forms without the inserts (s4, s3) for phosphorylation by cdk5
followed by GSK-3 at Thr231 and Ser262, the two major sites
involved in the binding of tau to microtubules. The combinedaction of these two protein kinases, which is believed to be in-
volved in the abnormal hyperphosphorylation of tau in AD
[26,28,37], caused considerably more inhibition (80%) of
binding to microtubules of tau isoforms with two amino termi-
nal inserts than tau isoforms lacking these inserts (40%)
(Table 1). Previous studies have also been consistent with the
presence of one or both amino terminal inserts making tau a
Fig. 6. Comparison of the release of microtubule-bound wild-type s4L
and diﬀerent s4L mutants after phosphorylation by cdk5 and GSK-3.
s4L (A), s4L(Ala231) (B), s4L(Ala235) (C) and s4L(Ala262) (D) were
bound to taxol-stabilized microtubules and then phosphorylated by the
ﬁrst and second kinases as in Fig. 4. The reactions were stopped and the
levels of wild-type and mutant taus that remained bound to MT
assessed as in Fig. 4. All values are expressed as a percentage of the
binding observed with MT-bound non-phosphorylated-s4L (100%).
Data (means ± S.D.) are from four diﬀerent experiments.
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kinases [38]. The presence of both the extra microtubule bind-
ing repeat (4R taus) and as well as the amino terminal inserts
make tau a more favorable substrate for sequestration by the
AD abnormally hyperphosphorylated tau [39] and its self-
assembly into tangles of PHF [40].
The present study showed that the phosphorylation of sites
in the proline-rich region (Thr231/Ser235) and the microtubule
binding repeats (Ser262/Ser356) but neither in the amino
terminal (Ser46) nor carboxy terminal tail (Ser396/Ser404,
Ser422) regions were decreased in MT-bound tau as compared
to free tau. This decreased phosphorylation of the MT-bound
s4L and s3L, which is consistent with the retardation of phos-
phorylation of MT-bound s4L at Ser262 by MARK110 kinase
reported previously [41], also resulted in about one third
(30%) lesser release of these proteins from MT than the bind-
ing of these tau isoforms to MT after phosphorylation by cdk5
plus GSK-3. We found that in MT-bound tau, cdk5 prep-
hosphorylated tau and unmodiﬁed tau were phosphorylated
to the same extent by GSK-3. Thus, Thr231/Ser235, which
on phosphorylation by cdk5 become more accessible for subse-
quent phosphorylation by GSK-3 in free tau with N-terminal
inserts, are protected in MT-bound tau.
The role of Thr231 and Ser262 phosphorylations in the inhi-
bition of the binding of tau to MT was conﬁrmed by studies in
which these sites were mutated to Ala. While on phosphoryla-
tion by ckd5 plus GSK-3 MT-bound s4L remained bound to
MT to the extent of 50%, binding of Ala231 and Ala262 mu-
tant taus to MT was increased by 25% and 13%, respec-
tively. Hence, in MT-bound tau, both of these sites appeared
to be involved in controlling tau binding to MT. It is impor-
tant to note that, in MT-bound tau, Thr231 contributes more
(25%) than Ser262 (13%) in the inhibition of binding of tau
to MT when phosphorylated, whereas in a previous study [16],
phosphorylation of free tau at Thr231 and Ser262 was found
to contribute 26% and 33%, respectively, of the overall
inhibition of tau binding to microtubules. Thus, free tau and
MT-bound tau may attain diﬀerent conformations upon phos-
phorylation which, in turn, bind diﬀerently to microtubules.It appears that not all sites which have been reported to be
phosphorylated in PHF-tau directly aﬀect the binding of tau
to microtubules. We found that the sites Ser46, Ser396, Ser404
and Ser422 are phosphorylated to the same extent in both
free and microtubule-bound tau. On the contrary, Thr231/
Ser235 and Ser262/Ser356 are phosphorylated to a higher extent
in free tau compared to MT-bound tau. These results suggest
that both the proline-rich region and repeat regions are directly
involved in the binding of tau to microtubules, whereas the N-
terminal and C-terminal regions exert only indirect eﬀect to this
binding. These ﬁndings are consistent with those of Goode et al.
[42], who showed that functional interaction between proline-
rich and repeat regions of tau enhanced microtubule binding
and assembly. Phosphorylation of tau at Ser396 and the subse-
quent reduction of its binding to MT reported previously [43] is
probably an example of indirect involvement of the C-terminal
region in the binding of tau to MT.
Ser262 is the only site abnormally hyperphosphorylated in
the microtubule binding repeat region of tau in AD. This site
is believed to play a major role in regulating the binding of tau
to MT [41]. GSK-3 and cdk5 have been implicated as two
major protein kinases involved in the abnormal hyperphosph-
orylation of tau in AD. The phosphorylation of tau at Ser262
by these two protein kinases, however, has been controversial
[27,29–35]. The present study, employing both recombinant
cdk5 and GSK-3 and these protein kinases puriﬁed by immu-
noprecipitation, have demonstrated that GSK-3a and neither
GSK-3b nor cdk5 could phosphorylate Ser262 in tau. The
GSK-3 isolated from brain is a mixture of GSK-3a and
GSK-3b. The phosphorylation of tau at Ser262 by GSK-3 iso-
lated from brain reported previously [29,32–34] was most
probably due to GSK-3a and not GSK-3b in the preparations.
The present study suggests a possible speciﬁc role of GSK-3a
in the phosphorylation of tau at Ser262.
The isoform composition of tau is altered in diﬀerent neuro-
degenerative disorders that are characterized by tau pathology,
and in every one of these diseases, the tau is abnormally hyper-
phosphorylated (see Ref. [8]). Furthermore, several missense
or deletion mutations, especially in the microtubule binding re-
gions of tau, and the segregation of these mutations with the
disease in the hereditary frontotemporal dementia with Parkin-
sonism linked to chromosome 17 (FTDP-17) have been ob-
served [44]. In light of the present study, which shows the
substrate regulation of the phosphorylation of tau at sites that
aﬀect its biological activity, we speculate the involvement of
this process in the pathogenesis of Alzheimer disease and re-
lated tauopathies in which the isoforms of the composition
of tau is altered.
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